[go: up one dir, main page]

AR127470A1 - Inhibidores de lrrk2 - Google Patents

Inhibidores de lrrk2

Info

Publication number
AR127470A1
AR127470A1 ARP220102914A ARP220102914A AR127470A1 AR 127470 A1 AR127470 A1 AR 127470A1 AR P220102914 A ARP220102914 A AR P220102914A AR P220102914 A ARP220102914 A AR P220102914A AR 127470 A1 AR127470 A1 AR 127470A1
Authority
AR
Argentina
Prior art keywords
lrrk2 inhibitors
compounds
lrrk2
parkinson
disease
Prior art date
Application number
ARP220102914A
Other languages
English (en)
Inventor
Thomas Jensen
Mikkel Jessing
Wanwan Yu
Diaz David Rodriguez
Jacob Nielsen
Christopher Richard Jones
Thomas Andersen
Mikkel Fog Jacobsen
Original Assignee
H Lundbeck As
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As, Vernalis R&D Ltd filed Critical H Lundbeck As
Publication of AR127470A1 publication Critical patent/AR127470A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (1). Los compuestos se consideran útiles para el tratamiento de enfermedades asociadas con LRRK2 tales como la enfermedad de Parkinson. Reivindicación 16: Una composición farmacéutica que comprende un compuesto de acuerdo con una cualquiera de las reivindicaciones 1 a 15 anteriores y uno o más portadores farmacéuticamente aceptables.
ARP220102914A 2021-10-27 2022-10-26 Inhibidores de lrrk2 AR127470A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21204970 2021-10-27
EP22201380 2022-10-13

Publications (1)

Publication Number Publication Date
AR127470A1 true AR127470A1 (es) 2024-01-31

Family

ID=84272359

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102914A AR127470A1 (es) 2021-10-27 2022-10-26 Inhibidores de lrrk2

Country Status (7)

Country Link
US (2) US11780851B2 (es)
EP (1) EP4422750A1 (es)
JP (1) JP2024541934A (es)
AR (1) AR127470A1 (es)
BR (1) BR112023012947A2 (es)
TW (1) TW202330549A (es)
WO (1) WO2023073013A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024541934A (ja) 2021-10-27 2024-11-13 ハー・ルンドベック・アクチエゼルスカベット Ｌｒｒｋ２阻害剤
CN117425660A (zh) * 2022-05-18 2024-01-19 上海翊石医药科技有限公司 一种芳杂环类化合物及其中间体、药物组合物和用途
WO2024056775A1 (en) 2022-09-15 2024-03-21 H. Lundbeck A/S Macrocyclic leucine-rich repeat kinase 2 (lrrk2) inhibitors
AR132487A1 (es) * 2023-04-20 2025-07-02 H Lundbeck As Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2)
WO2024218296A1 (en) * 2023-04-20 2024-10-24 H. Lundbeck A/S Combination treatments comprising administration of leucine-rich repeat kinase 2 (lrrk2) inhibitors
CN119552171A (zh) * 2023-09-04 2025-03-04 浙江养生堂天然药物研究所有限公司 大环吡唑并嘧啶类化合物及其用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029728T2 (en) * 2011-09-30 2017-03-28 Ipsen Pharma Sas Macrocyclic LRRK2 kinase inhibitors
BR112014032913A2 (pt) 2012-06-29 2017-06-27 Pfizer novas 4-(amino-substituídas)-7h-pirrolo[2,3-d]pirimidinas como inibidores de lrrk2
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
WO2014134774A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134772A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134776A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014137728A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN105143232A (zh) 2013-03-15 2015-12-09 益普生制药股份有限公司 大环的lrrk2激酶抑制剂
WO2015026683A1 (en) 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
EP3068389B1 (en) 2013-11-14 2019-10-02 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
UA118369C2 (uk) 2014-01-29 2019-01-10 Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед Сполуки, що інгібують активність lrrk2 кінази
JP6474826B2 (ja) 2014-01-29 2019-02-27 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 化合物
US10954240B2 (en) 2014-09-03 2021-03-23 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
BR112017005299A2 (pt) 2014-09-17 2017-12-12 Ipsen Pharma Sas inibidores de lrrk2 cinase macrocíclicos
EP3778604B1 (en) 2015-02-13 2026-01-07 Dana-Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same
CA2993269A1 (en) 2015-07-23 2017-01-26 Glaxosmithkline Intellectual Property Development Limited Compounds
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
AU2016369584A1 (en) 2015-12-16 2018-07-19 Southern Research Institute Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof
PE20190395A1 (es) 2016-06-16 2019-03-13 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
JP2020506966A (ja) 2017-01-25 2020-03-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 化合物
BR112019015278A2 (pt) 2017-01-25 2020-04-14 Glaxosmithkline Ip Dev Ltd compostos
JP2020505399A (ja) 2017-01-25 2020-02-20 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 化合物
WO2018155916A2 (ko) 2017-02-22 2018-08-30 재단법인 대구경북첨단의료산업진흥재단 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
US20200157081A1 (en) 2017-05-24 2020-05-21 Denali Therapeutics Inc. Compounds, compositions and methods
EP3652179A1 (en) * 2017-07-14 2020-05-20 GlaxoSmithKline Intellectual Property Development Ltd Inhibitors of leucine rich repeat kinase 2
EP3694331B1 (en) 2017-10-11 2022-11-16 Merck Sharp & Dohme LLC Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
US11161854B2 (en) 2017-10-11 2021-11-02 Merck Sharp & Dohme Corp. Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
CN111433208B (zh) 2017-12-05 2023-06-30 奥斯考泰克公司 作为lrrk2抑制剂的吡咯并(吡唑并)嘧啶衍生物
EP3883573B1 (en) 2018-11-19 2024-07-31 Dana-Farber Cancer Institute, Inc. Macrocyclic inhibitors of dyrk1a
JP2024541934A (ja) 2021-10-27 2024-11-13 ハー・ルンドベック・アクチエゼルスカベット Ｌｒｒｋ２阻害剤
CN117425660A (zh) 2022-05-18 2024-01-19 上海翊石医药科技有限公司 一种芳杂环类化合物及其中间体、药物组合物和用途
WO2023224894A1 (en) 2022-05-20 2023-11-23 Merck Sharp & Dohme Llc Macrocycles as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof

Also Published As

Publication number Publication date
WO2023073013A1 (en) 2023-05-04
TW202330549A (zh) 2023-08-01
US20230144725A1 (en) 2023-05-11
US20230416272A1 (en) 2023-12-28
JP2024541934A (ja) 2024-11-13
US11780851B2 (en) 2023-10-10
BR112023012947A2 (pt) 2024-04-30
EP4422750A1 (en) 2024-09-04
US11993612B2 (en) 2024-05-28
WO2023073013A9 (en) 2023-08-17
WO2023073013A8 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
AR127470A1 (es) Inhibidores de lrrk2
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
AR128931A1 (es) Inhibidores del factor b del complemento y usos de los mismos
CL2022001741A1 (es) Compuestos cíclicos y métodos de uso de estos
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
CO6670589A2 (es) Compuestos para reducir la producción de beta-amiloide
MX2021011606A (es) Compuestos dirigidos a prmt5.
CO2022000749A2 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
CL2021000844A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
DOP2019000076A (es) DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO
DOP2024000102A (es) Compuestos macrocíclicos con actividad inhibidora de la farnesiltransferasa
MX2024015493A (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1
CL2022002975A1 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
MX2025010799A (es) Inhibidores de acilsulfonamida para lisina acetiltransferasa 6a (kat6a)
MX2024007929A (es) Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead.
AR128109A1 (es) Spiros y análogos relacionados para inhibir yap / taz-tead
CL2025000161A1 (es) Compuestos cíclicos y métodos de utilización de estos.
CO2025003099A2 (es) Compuestos para el tratamiento del cáncer
DOP2019000299A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
AR130483A1 (es) Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2)
AR115921A1 (es) Ácido isolitocólico o ácido isoalolitocólico y derivados deuterados de los mismos para prevenir y tratar enfermedades asociadas a clostridium difficile
AR128100A1 (es) Compuestos para el tratamiento de la pérdida del cabello
MX2021009584A (es) Nuevos derivados de triterpeno como inhibidores del virus de la inmunodeficiencia humana (vih).
MX2022005843A (es) Derivados de bencilamida como inhibidores del receptor i del factor de crecimiento transformante beta/ cinasa similar al receptor de activina 5 (alk5).
AR132909A1 (es) Métodos de tratamiento de enfermedades inflamatorias

Legal Events

Date Code Title Description
FB Suspension of granting procedure